Beckman Coulter Buys Cardiac Test Developer Biosite For $1.55 Billion
This article was originally published in The Gray Sheet
Executive Summary
In a $1.55 billion acquisition plan announced March 25, Beckman Coulter looks to combine its strength as a leading manufacturer of lab instruments with the complementary expertise of diagnostic test developer Biosite